A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation

Johan Nilsson; Victoria Jernryd; Guangqi Qin; Audrius Paskevicius; Carsten Metzsch; Trygve Sjöberg; Stig Steen

doi:10.1038/s41467-020-16782-9

Nature Communications (Jun 2020)

A nonrandomized open-label phase 2 trial of nonischemic heart preservation for human heart transplantation

Johan Nilsson,
Victoria Jernryd,
Guangqi Qin,
Audrius Paskevicius,
Carsten Metzsch,
Trygve Sjöberg,
Stig Steen

Affiliations

Johan Nilsson: Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital
Victoria Jernryd: Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital
Guangqi Qin: Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital
Audrius Paskevicius: Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital
Carsten Metzsch: Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital
Trygve Sjöberg: Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital
Stig Steen: Department of Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital

DOI: https://doi.org/10.1038/s41467-020-16782-9
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 8

Abstract

Read online

Ischemia and reperfusion damage contribute to early graft dysfunction and recipient’s death. Here the authors show the feasibility and safety of a non-ischemic heart preservation method for heart transplantation in a non-randomized trial.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal